ArticleMikrochimica acta2025
Ultra-sensitive impedimetric biosensor for HCV detection in patient samples coupled with double-noble nanoparticles on carbon ink-patterned paper electrode.
Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An ultra-sensitive impedimetric paper-based biosensor for the rapid detection of hepatitis C virus (HCV) core antigen in human serum, integrating double-noble Silver–AuNPs onto a carbon ink-patterned paper electrode is presented. The sensing interface is developed by immobilizing anti-HCV core antibodies onto a silver–gold nanoparticle (Ag–AuNP)-modified electrode surface, which serves as the biorecognition layer. This configuration enables label-free detection of antigen–antibody interactions using electrochemical impedance spectroscopy (EIS). Sensor performance was systematically optimized with respect to antigen concentration (0.1 ng/mL–500 µg/mL), incubation temperature, reaction time, and operational stability under repeated measurements. The optimized platform achieved a low limit of detection of 10.21 ng/mL and a limit of quantification of 34.05 ng/mL, with a wide linear dynamic range suitable for clinically relevant HCV core antigen levels. Analytical validation using HCV-positive clinical serum samples demonstrated high diagnostic accuracy and specificity against non-HCV samples. The proposed Silver–AuNPs based impedimetric immunosensor offers a low-cost, portable, and time-efficient alternative to conventional laboratory assays, with strong potential for point-of-care screening and large-scale surveillance of HCV infection, particularly in resource-limited settings.
Indexed as
Identifiers
41454112What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.